Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
2007; Elsevier BV; Volume: 25; Issue: 20 Linguagem: Inglês
10.1016/j.vaccine.2007.02.050
ISSN1873-2518
AutoresAndrew Catanzaro, Mario Roederer, Richard A. Koup, Robert T. Bailer, Mary E. Enama, Martha Nason, Julie E. Martin, Steve Rucker, Charla Andrews, Phillip L. Gomez, John R. Mascola, Gary J. Nabel, Barney S. Graham,
Tópico(s)Immunotherapy and Immune Responses
ResumoNeedle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.
Referência(s)